Shenzhen Hepalink agreed to acquire Scientific Protein Laboratories LLC. for $337.5 million to strengthen the quality of Shenzhen’s blood clot prevention drug

December 27, 2013 Leave a comment

ecember 26, 2013, 7:25 a.m. ET

Heparin Maker Shenzhen Hepalink to Acquire U.S. Supplier

By Everdeen Mason

Shenzhen Hepalink Pharmaceutical Co. agreed to acquire Scientific Protein Laboratories LLC. for $337.5 million to strengthen the quality of Shenzhen’s blood clot prevention drug. Shenzhen, the Chinese maker of blood-thinner Heparin, is buying Scientific Protein, a supplier of pharmaceutical ingredients with 204 employees based in Wisconsin. Both companies say the deal will expand their markets and allow better access to raw materials to manufacture heparin. Prior to its initial public offering more than three years ago, Shenzhen battled claims that its product, made from pig intestines, is tainted. With the deal “Hepalink will be able to further enhance the stability and safety of the supply of the heparin product raw materials,” said Shenzhen Chief Executive Li Li. The company will also be able to open new markets and invest more in research and development, he added. Scientific Protein said there will be no changes to its operations after the acquisition is complete. The expected close of the deal wasn’t announced Thursday.

Filed under Health

Unknown's avatarAbout bambooinnovator
Kee Koon Boon (“KB”) is the co-founder and director of HERO Investment Management which provides specialized fund management and investment advisory services to the ARCHEA Asia HERO Innovators Fund (www.heroinnovator.com), the only Asian SMID-cap tech-focused fund in the industry. KB is an internationally featured investor rooted in the principles of value investing for over a decade as a fund manager and analyst in the Asian capital markets who started his career at a boutique hedge fund in Singapore where he was with the firm since 2002 and was also part of the core investment committee in significantly outperforming the index in the 10-year-plus-old flagship Asian fund. He was also the portfolio manager for Asia-Pacific equities at Korea’s largest mutual fund company. Prior to setting up the H.E.R.O. Innovators Fund, KB was the Chief Investment Officer & CEO of a Singapore Registered Fund Management Company (RFMC) where he is responsible for listed Asian equity investments. KB had taught accounting at the Singapore Management University (SMU) as a faculty member and also pioneered the 15-week course on Accounting Fraud in Asia as an official module at SMU. KB remains grateful and honored to be invited by Singapore’s financial regulator Monetary Authority of Singapore (MAS) to present to their top management team about implementing a world’s first fact-based forward-looking fraud detection framework to bring about benefits for the capital markets in Singapore and for the public and investment community. KB also served the community in sharing his insights in writing articles about value investing and corporate governance in the media that include Business Times, Straits Times, Jakarta Post, Manual of Ideas, Investopedia, TedXWallStreet. He had also presented in top investment, banking and finance conferences in America, Italy, Sydney, Cape Town, HK, China. He has trained CEOs, entrepreneurs, CFOs, management executives in business strategy & business model innovation in Singapore, HK and China.

Leave a comment